TGTX - TG Therapeutics, Inc.
9.00 -0.05 (-0.55%)
After hours: 6:59PM EDT
| Previous Close | 8.95 |
| Open | 9.00 |
| Bid | 8.85 x 3200 |
| Ask | 9.05 x 1000 |
| Day's Range | 8.60 - 9.18 |
| 52 Week Range | 7.25 - 17.35 |
| Volume | 1,503,022 |
| Avg. Volume | 1,091,790 |
| Market Cap | 746.608M |
| Beta | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.17 |
- ACCESSWIRE•3 days ago
Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Wall Street was cheering for Teva on Monday after the Israeli pharmaceutical giant received FDA approval finally for its migraine drug Ajovy. Shares of ...
Market Realist•13 days agoWhy Spectrum Pharmaceuticals Stock Rose ~5% on September 6
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
- Benzinga•25 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results
Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) gained about 1.5 percent. ...
- American City Business Journals•28 days ago
New York City stocks that are driving Wall Street's latest bull run
Sirius XM Holdings was the New York City's biggest gainer, rising from 15 cents per share on March 9, 2009 to $6.94 on Aug. 21 of this year, an increase of 4,521 percent.
- Thomson Reuters StreetEvents•last month
Edited Transcript of TGTX earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 TG Therapeutics Inc Earnings Call
- Zacks•last month
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•last month
Consolidated Research: 2018 Summary Expectations for Allegiance Bancshares, TG Therapeutics, JELD-WEN Holding, Eagle Bulk Shipping, Bryn Mawr Bank, and Surmodics — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allegiance ...
- Motley Fool•last month
3 Biotech Stocks With Major Catalysts Incoming
Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.
- Associated Press•last month
TG Therapeutics: 2Q Earnings Snapshot
The New York-based company said it had a loss of 59 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•last month
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results
NEW YORK, Aug. 07, 2018-- TG Therapeutics, Inc. today announced its financial results for the second quarter ended June 30, 2018 and recent company developments. Michael S. Weiss, the Company's Executive ...
- GlobeNewswire•last month
TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis
TG Therapeutics, Inc. (TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in patients with relapsing forms of Multiple Sclerosis (RMS). While target enrollment has been reached, in order to provide an opportunity for patients already identified to participate, enrollment is expected to continue until mid-September.
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.
- Zacks•2 months ago
Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options
Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green.
- Insider Monkey•3 months ago
This Biotech Investor’s Picks Returned 31% in Q1; Here Are Its New Bets
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns. We calculate a fund’s returns by taking into account the long positions in companies with a market cap above $1.0 billion and Kolchinsky’s RA Capital Management was the best performing fund among those in our database in […]
- ACCESSWIRE•3 months ago
TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).
- Motley Fool•3 months ago
3 Cancer Stocks That Could Soar in the Second Half of 2018
Keep your eyes open for big catalysts that could give these biotech stocks a push in the right direction.
- Motley Fool•4 months ago
ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today
A presentation at the highly watched conference is sparking investor optimism.
